Jun Watanabe1, Yusuke Suwa, Mitsuyoshi Ota, Atsushi Ishibe, Hidenobu Masui, Kaoru Nagahori, Yukio Tsuura, Itaru Endo. 1. 1 Department of Surgery, Yokosuka Kyosai Hospital, Yokosuka, Japan 2 Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Japan 3 Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan 4 Department of Pathology, Yokosuka Kyosai Hospital, Yokosuka, Japan.
Abstract
BACKGROUND: Mixed adenoneuroendocrine carcinoma of the colon and rectum is a very rare type of tumor. OBJECTIVE: The aim of the present study was to evaluate the clinicopathological characteristics and prognosis of mixed adenoneuroendocrine carcinomas of the colon and rectum. DESIGN: This was a retrospective case-matched analysis (from March 2007 to December 2013). SETTINGS: This study was conducted at Yokosuka Kyosai Hospital. PATIENTS: One thousand three hundred six consecutive patients with a preoperative diagnosis of colorectal cancer and who underwent tumor resection were enrolled in the present study. Each patient diagnosed with mixed adenoneuroendocrine carcinoma was 1:2 matched with 2 counterparts who had been diagnosed with adenocarcinoma. INTERVENTION: Immunohistochemical staining for neuroendocrine markers (chromogranin A, synaptophysin, and CD56) was performed. Cases in which the neuroendocrine component accounted for >30% of the tumor were diagnosed as mixed adenoneuroendocrine carcinomas. RESULTS: Among 1306 patients, 42 patients (3.2%) were diagnosed with mixed adenoneuroendocrine carcinoma and were compared with 84 patients with adenocarcinoma who had been randomly case matched. The average Ki-67-labeling index value was 78.0% (range, 30.0%-99.0%). Chromogranin A, synaptophysin, and CD56 positivity were observed in 42.9% (18/42), 81.0% (34/42), and 33.3% (14/42) of the tumors. Both the disease-free survival and overall survival were significantly worse for mixed adenoneuroendocrine carcinoma than for adenocarcinoma. Ten patients underwent treatment with oxaliplatin-based chemotherapy. The response rate was 40.0%; the median progression-free survival and overall survival were 6.3 months and 18.1 months. LIMITATIONS: This was a retrospective single-institution study that included a limited number of cases. The treatment regimens used included different types of oxaliplatin-based chemotherapy. CONCLUSION: Mixed adenoneuroendocrine carcinoma of the colon and rectum has a poor prognosis after curative resection and should be distinguished from adenocarcinoma.
BACKGROUND: Mixed adenoneuroendocrine carcinoma of the colon and rectum is a very rare type of tumor. OBJECTIVE: The aim of the present study was to evaluate the clinicopathological characteristics and prognosis of mixed adenoneuroendocrine carcinomas of the colon and rectum. DESIGN: This was a retrospective case-matched analysis (from March 2007 to December 2013). SETTINGS: This study was conducted at Yokosuka Kyosai Hospital. PATIENTS: One thousand three hundred six consecutive patients with a preoperative diagnosis of colorectal cancer and who underwent tumor resection were enrolled in the present study. Each patient diagnosed with mixed adenoneuroendocrine carcinoma was 1:2 matched with 2 counterparts who had been diagnosed with adenocarcinoma. INTERVENTION: Immunohistochemical staining for neuroendocrine markers (chromogranin A, synaptophysin, and CD56) was performed. Cases in which the neuroendocrine component accounted for >30% of the tumor were diagnosed as mixed adenoneuroendocrine carcinomas. RESULTS: Among 1306 patients, 42 patients (3.2%) were diagnosed with mixed adenoneuroendocrine carcinoma and were compared with 84 patients with adenocarcinoma who had been randomly case matched. The average Ki-67-labeling index value was 78.0% (range, 30.0%-99.0%). Chromogranin A, synaptophysin, and CD56 positivity were observed in 42.9% (18/42), 81.0% (34/42), and 33.3% (14/42) of the tumors. Both the disease-free survival and overall survival were significantly worse for mixed adenoneuroendocrine carcinoma than for adenocarcinoma. Ten patients underwent treatment with oxaliplatin-based chemotherapy. The response rate was 40.0%; the median progression-free survival and overall survival were 6.3 months and 18.1 months. LIMITATIONS: This was a retrospective single-institution study that included a limited number of cases. The treatment regimens used included different types of oxaliplatin-based chemotherapy. CONCLUSION: Mixed adenoneuroendocrine carcinoma of the colon and rectum has a poor prognosis after curative resection and should be distinguished from adenocarcinoma.
Authors: Melissa Frizziero; Xin Wang; Bipasha Chakrabarty; Alexa Childs; Tu V Luong; Thomas Walter; Mohid S Khan; Meleri Morgan; Adam Christian; Mona Elshafie; Tahir Shah; Annamaria Minicozzi; Wasat Mansoor; Tim Meyer; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara Journal: World J Gastroenterol Date: 2019-10-21 Impact factor: 5.742
Authors: Panpan Zhang; Zhongwu Li; Jie Li; Jian Li; Xiaotian Zhang; Zhihao Lu; Yu Sun; Yan Li; Jun Zhou; Xicheng Wang; Zhi Peng; Lin Shen; Ming Lu Journal: Cancer Med Date: 2021-06-10 Impact factor: 4.452